Targeting SMAD3 Improves Response to Oxaliplatin in Esophageal Adenocarcinoma Models by Impeding DNA Repair

CONCLUSIONS: Our results identify SMAD3 as a promising therapeutic target for future combination strategies for the treatment of patients with EAC.PMID:38592373 | DOI:10.1158/1078-0432.CCR-24-0027

Source: Clinical Cancer Research - April 9, 2024 Category: Cancer & Oncology Authors: Farah Ballout Heng Lu Nadeem Bhat Lei Chen Dunfa Peng Zheng Chen Steven Chen Xiaodian Sun Silvia Giordano Simona Corso Alexander Zaika Oliver McDonald Alan S Livingstone Wael El-Rifai Source Type: research